In-Silico Structure Database (LMISSD)

Back
Overview
Browse
Search

LMISSD: Sum Composition Results

Abbreviation Formula Mass Main Class Sub Class
Galβ1-4GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 44:1;O2 C84H153N3O33 1732.038644 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:1;O2 C84H153N3O33 1732.038644 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C82H148N2O36 1736.981190 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O37 1737.940054 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O36 1749.976439 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O36 1749.976439 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 38:1;O2 C82H148N2O37 1752.976105 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C80H143N3O38 1753.934969 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C84H152N2O36 1765.012490 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O37 1765.971354 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O36 1778.007739 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O36 1778.007739 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 40:1;O2 C84H152N2O37 1781.007405 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C82H147N3O38 1781.966269 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:2;O2 C86H154N2O36 1791.028140 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:1;O2 C86H156N2O36 1793.043790 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O37 1794.002654 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3(GlcNAcβ1-6)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C82H146N4O38 1794.961518 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C82H146N4O38 1794.961518 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O36 1806.039039 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O36 1806.039039 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 42:2;O2 C86H154N2O37 1807.023055 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 42:1;O2 C86H156N2O37 1809.038705 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C84H151N3O38 1809.997569 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:2;O2 C88H158N2O36 1819.059440 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:1;O2 C88H160N2O36 1821.075090 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O37 1822.033954 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O37 1822.033954 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O37 1822.033954 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O37 1822.033954 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O37 1822.033954 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C86H155N3O37 1822.033954 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]